GLP-1 drugs aren't for everyone: what the data actually shows

What's this video probably claiming?

Based on the caption "no issues with people using GLP-1, it's not just for me," this creator appears to be either explaining why GLP-1 receptor agonists didn't work for them personally, or distancing themselves from the broader trend of GLP-1 use for weight loss. The framing suggests a personal experience, possibly involving side effects, cost barriers, or simply not being a candidate for these medications. This is a common TikTok narrative arc: creator tries a hyped treatment, shares a vulnerable "it wasn't for me" moment, and implicitly validates others who do use it. That's a reasonable human story. The problem is when personal anecdotes get treated as clinical guidance, either in the direction of "everyone should try this" or "this drug failed me so maybe it's not worth it." Neither conclusion maps cleanly onto the actual evidence base for GLP-1 medications.

What does the science actually show?

GLP-1 receptor agonists have some of the strongest weight-loss trial data in modern pharmacology. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4mg weekly produced mean weight loss of 14.9% of body weight over 68 weeks versus 2.4% for placebo. Tirzepatide data from the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) was even more striking, with the 15mg dose producing 22.5% mean weight reduction at 72 weeks. These aren't marginal effects. But "works on average" doesn't mean "works for everyone." Roughly 10-15% of trial participants are classified as low responders, losing less than 5% of body weight. Side effects, primarily nausea, vomiting, and gastrointestinal distress, cause discontinuation in a meaningful subset of patients. The SELECT trial (Lincoff et al., 2023, NEJM) added cardiovascular outcome data, showing a 20% relative risk reduction in major adverse cardiac events with semaglutide in overweight adults without diabetes.

Where does the social media noise diverge from clinical reality?

TikTok GLP-1 content tends to polarize hard. You either get transformation videos framing these drugs as effortless miracles, or cautionary tales presenting individual negative experiences as evidence the drugs are dangerous or overhyped. Both framings miss the clinical picture. The real data shows meaningful efficacy for a large portion of users with a real side effect burden that's manageable for most but genuinely difficult for some. The gastrointestinal side effect profile, reported in up to 44% of semaglutide users in STEP trials, is not trivial. Pancreatitis risk, though rare, is documented. The FDA label carries warnings for personal or family history of medullary thyroid carcinoma. None of this means the drugs are dangerous at a population level, but it does mean that "no issues with people using GLP-1" as a blanket framing is clinically incomplete. Real prescribing involves contraindication screening, dose titration over months, and monitoring. That context rarely survives a 60-second clip.

What should you actually know?

If you're considering a GLP-1 medication, the personal experience of a TikTok creator, whether positive or negative, is genuinely one of the least useful data points available to you. What matters: your baseline BMI or weight-related comorbidities (FDA-approved indications generally require BMI 30 or above, or 27 with at least one comorbidity), your personal and family medical history, and whether you have access to consistent medical oversight. These drugs require titration schedules that span months. Stopping abruptly is associated with weight regain, as shown in the STEP 4 withdrawal extension (Rubino et al., 2021, NEJM), where participants regained approximately two-thirds of lost weight within a year of stopping. Cost and access remain real barriers. Compounded versions exist but are not equivalent to FDA-approved branded formulations in terms of regulatory oversight. A clinician-supervised approach, not a TikTok narrative, is the appropriate starting point for this decision.